Sirnaomics Ltd. (HK:2257) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Sirnaomics Ltd., a leader in RNA therapeutics, has reported positive interim results for the first half of 2024, highlighting advancements in their clinical pipeline with successful trials for their lead cancer treatment drug candidates, STP705 and STP707. The company is expanding its reach with a focus on the U.S. and Asia, leveraging proprietary delivery platforms to develop treatments for a variety of diseases including oncology, fibrosis, and viral infections. Sirnaomics is also contributing to the growth of RNA medicine by collaborating on mRNA vaccine development and new clinical programs.
For further insights into HK:2257 stock, check out TipRanks’ Stock Analysis page.